Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1 specific cytotoxic T-cells identified by peptide-MHC-class-I tetramers

Bohnenkamp H, Coleman J, Burchell J, Taylor-Papadimitriou J, Noll T (2004)
Cellular Immunology 231(1-2): 112-125.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
DOI
Autor*in
Bohnenkamp, H; Coleman, J; Burchell, J; Taylor-Papadimitriou, J; Noll, Thomas
Einrichtung
Technische Fakultät > AG Zellkulturtechnik
Erscheinungsjahr
2004
Zeitschriftentitel
Cellular Immunology
Band
231
Ausgabe
1-2
Seite(n)
112-125
ISSN
0008-8749
Page URI
https://pub.uni-bielefeld.de/record/2395259

Zitieren

Bohnenkamp H, Coleman J, Burchell J, Taylor-Papadimitriou J, Noll T. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1 specific cytotoxic T-cells identified by peptide-MHC-class-I tetramers. Cellular Immunology. 2004;231(1-2):112-125.
Bohnenkamp, H., Coleman, J., Burchell, J., Taylor-Papadimitriou, J., & Noll, T. (2004). Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1 specific cytotoxic T-cells identified by peptide-MHC-class-I tetramers. Cellular Immunology, 231(1-2), 112-125. https://doi.org/10.1016/j.cellimm.2004.12.007
Bohnenkamp, H, Coleman, J, Burchell, J, Taylor-Papadimitriou, J, and Noll, Thomas. 2004. “Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1 specific cytotoxic T-cells identified by peptide-MHC-class-I tetramers”. Cellular Immunology 231 (1-2): 112-125.
Bohnenkamp, H., Coleman, J., Burchell, J., Taylor-Papadimitriou, J., and Noll, T. (2004). Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1 specific cytotoxic T-cells identified by peptide-MHC-class-I tetramers. Cellular Immunology 231, 112-125.
Bohnenkamp, H., et al., 2004. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1 specific cytotoxic T-cells identified by peptide-MHC-class-I tetramers. Cellular Immunology, 231(1-2), p 112-125.
H. Bohnenkamp, et al., “Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1 specific cytotoxic T-cells identified by peptide-MHC-class-I tetramers”, Cellular Immunology, vol. 231, 2004, pp. 112-125.
Bohnenkamp, H., Coleman, J., Burchell, J., Taylor-Papadimitriou, J., Noll, T.: Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1 specific cytotoxic T-cells identified by peptide-MHC-class-I tetramers. Cellular Immunology. 231, 112-125 (2004).
Bohnenkamp, H, Coleman, J, Burchell, J, Taylor-Papadimitriou, J, and Noll, Thomas. “Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1 specific cytotoxic T-cells identified by peptide-MHC-class-I tetramers”. Cellular Immunology 231.1-2 (2004): 112-125.

14 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Modern strategies and capabilities for activation of the immune response against tumor cells.
Sennikov SV, Khantakova JN, Kulikova EV, Obleukhova IA, Shevchenko JA., Tumour Biol 39(5), 2017
PMID: 28513301
Tumor-associated antigens: Tn antigen, sTn antigen, and T antigen.
Fu C, Zhao H, Wang Y, Cai H, Xiao Y, Zeng Y, Chen H., HLA 88(6), 2016
PMID: 27679419
Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells.
Tanida T, Tanemura M, Miyoshi E, Nagano H, Furukawa K, Nonaka Y, Akita H, Hama N, Wada H, Kawamoto K, Kobayashi S, Eguchi H, Mori M, Doki Y., Int J Oncol 46(1), 2015
PMID: 25354268
Preparation of triple-negative breast cancer vaccine through electrofusion with day-3 dendritic cells.
Zhang P, Yi S, Li X, Liu R, Jiang H, Huang Z, Liu Y, Wu J, Huang Y., PLoS One 9(7), 2014
PMID: 25036145
MUC1 immunotherapy.
Beatson RE, Taylor-Papadimitriou J, Burchell JM., Immunotherapy 2(3), 2010
PMID: 20635898
Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy.
Foster S, Duvall CL, Crownover EF, Hoffman AS, Stayton PS., Bioconjug Chem 21(12), 2010
PMID: 21043513
Down-regulation of beta-centractin might be involved in dendritic cells dysfunction and subsequent hepatocellular carcinoma immune escape: a proteomic study.
Weng YQ, Qiu SJ, Liu YK, Fan J, Gao Q, Tang ZY., J Cancer Res Clin Oncol 134(2), 2008
PMID: 17619203
Immunisation with 'naïve' syngeneic dendritic cells protects mice from tumour challenge.
Grimshaw MJ, Papazisis K, Picco G, Bohnenkamp H, Noll T, Taylor-Papadimitriou J, Burchell J., Br J Cancer 98(4), 2008
PMID: 18253127
Novel therapeutic strategies for treating esophageal adenocarcinoma: the potential of dendritic cell immunotherapy and combinatorial regimens.
Milano F, Krishnadath KK., Hum Immunol 69(10), 2008
PMID: 18703104
Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice.
Tian F, Wang L, Qin W, Wang F, Song B, Li Y, Wen W, Zhang Z, Zhu K, Zhang Q, Lee C, Zhong W, Guo Y, Wang H., Cancer Lett 271(2), 2008
PMID: 18675506
The cytotoxic T cell response to peptide analogs of the HLA-A*0201-restricted MUC1 signal sequence epitope, M1.2.
Mitchell MS, Lund TA, Sewell AK, Marincola FM, Paul E, Schroder K, Wilson DB, Kan-Mitchell J., Cancer Immunol Immunother 56(3), 2007
PMID: 16874487
Current approaches in dendritic cell generation and future implications for cancer immunotherapy.
Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, Thielemans K, Bonehill A., Cancer Immunol Immunother 56(10), 2007
PMID: 17503040
Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells.
Saito H, Dubsky P, Dantin C, Finn OJ, Banchereau J, Palucka AK., Breast Cancer Res 8(6), 2006
PMID: 17129372
Treatment of squamous carcinoma in mice with a vaccine enriched for cells that induce immunity to squamous carcinoma--a new vaccination strategy.
Chopra A, Kim TS, O-Sullivan I, Martinez D, Cohen EP., Int J Cancer 119(2), 2006
PMID: 16477635

62 References

Daten bereitgestellt von Europe PubMed Central.

Tolerogenic dendritic cells.
Steinman RM, Hawiger D, Nussenzweig MC., Annu. Rev. Immunol. 21(), 2001
PMID: 12615891
Current issues in delivering DCs for immunotherapy.
Barratt-Boyes SM, Figdor CG., Cytotherapy 6(2), 2004
PMID: 15203986
Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells.
Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N., J. Exp. Med. 193(2), 2001
PMID: 11208863
Dendritic cells in cancer immunotherapy.
Gunzer M, Grabbe S., Crit. Rev. Immunol. 21(1-3), 2001
PMID: 11642600
A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats.
Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J., J. Biol. Chem. 263(26), 1988
PMID: 3417635
Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin.
Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani EN, Wilson D., J. Biol. Chem. 265(25), 1990
PMID: 1697589
Structure and expression of the human polymorphic epithelial mucin gene: an expressed VNTR unit.
Lancaster CA, Peat N, Duhig T, Wilson D, Taylor-Papadimitriou J, Gendler SJ., Biochem. Biophys. Res. Commun. 173(3), 1990
PMID: 2268309
Isolation and characterization of mucin-like glycoprotein in human milk fat globule membrane.
Shimizu M, Yamauchi K., J. Biochem. 91(2), 1982
PMID: 7068573
Monoclonal antibodies to epithelial sialomucins recognize epitopes at different cellular sites in adenolymphomas of the parotid gland.
Zotter S, Hageman PC, Lossnitzer A, van den Tweel J, Hilkens J, Mooi WJ, Hilgers J., Int. J. Cancer Suppl. 3(), 1988
PMID: 2463227
Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration.
Correa I, Plunkett T, Vlad A, Mungul A, Candelora-Kettel J, Burchell JM, Taylor-Papadimitriou J, Finn OJ., Immunology 108(1), 2003
PMID: 12519300
The epithelial mucin, MUC1, is expressed on resting T lymphocytes and can function as a negative regulator of T cell activation.
Chang JF, Zhao HL, Phillips J, Greenburg G., Cell. Immunol. 201(2), 2000
PMID: 10831317
Mucin-1 is expressed on dendritic cells, both in vitro and in vivo.
Cloosen S, Thio M, Vanclee A, van Leeuwen EB, Senden-Gijsbers BL, Oving EB, Germeraad WT, Bos GM., Int. Immunol. 16(11), 2004
PMID: 15381671
A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas.
Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J., Int. J. Cancer 43(6), 1989
PMID: 2471698
Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases.
Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R., Mod. Pathol. 17(2), 2004
PMID: 14657952
Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin.
Noto H, Takahashi T, Makiguchi Y, Hayashi T, Hinoda Y, Imai K., Int. Immunol. 9(5), 1997
PMID: 9184925
Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.
Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO., Clin. Cancer Res. 4(2), 1998
PMID: 9516914
MUC1 and the immunobiology of cancer.
Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D, Smith M., J Mammary Gland Biol Neoplasia 7(2), 2002
PMID: 12463741
Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.
Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W., Blood 93(12), 1999
PMID: 10361129
Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice.
Heukamp LC, van der Burg SH, Drijfhout JW, Melief CJ, Taylor-Papadimitriou J, Offringa R., Int. J. Cancer 91(3), 2001
PMID: 11169964
Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes.
Muller MR, Grunebach F, Nencioni A, Brossart P., J. Immunol. 170(12), 2003
PMID: 12794115
Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines.
Brossart P, Bevan MJ., Blood 90(4), 1997
PMID: 9269778
Antigen presentation and T cell stimulation by dendritic cells.
Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S., Annu. Rev. Immunol. 20(), 2001
PMID: 11861614
Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches.
Constant SL, Bottomly K., Annu. Rev. Immunol. 15(), 1997
PMID: 9143690
Dendritic-cell control of pathogen-driven T-cell polarization.
Kapsenberg ML., Nat. Rev. Immunol. 3(12), 2003
PMID: 14647480
The molecular basis of T helper 1 and T helper 2 cell differentiation.
O'Garra A, Arai N., Trends Cell Biol. 10(12), 2000
PMID: 11121747
Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells.
Langenkamp A, Messi M, Lanzavecchia A, Sallusto F., Nat. Immunol. 1(4), 2000
PMID: 11017102
A human cell line from a pleural effusion derived from a breast carcinoma.
Soule HD, Vazguez J, Long A, Albert S, Brennan M., J. Natl. Cancer Inst. 51(5), 1973
PMID: 4357757
Breast tumor cell lines from pleural effusions.
Cailleau R, Young R, Olive M, Reeves WJ Jr., J. Natl. Cancer Inst. 53(3), 1974
PMID: 4412247
Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation.
Wiechelman KJ, Braun RD, Fitzpatrick JD., Anal. Biochem. 175(1), 1988
PMID: 3245570
Development of a standardized protocol for reproducible generation of matured monocyte-derived dendritic cells suitable for clinical application.
Bohnenkamp HR, Noll T., Cytotechnology 42(3), 2003
PMID: 19002934
Complexity of expression of antigenic determinants, recognized by monoclonal antibodies HMFG-1 and HMFG-2, in normal and malignant human mammary epithelial cells.
Burchell J, Durbin H, Taylor-Papadimitriou J., J. Immunol. 131(1), 1983
PMID: 6190927
Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin.
Burchell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A, Millis R, Lamport D., Cancer Res. 47(20), 1987
PMID: 2443241
Distinct subsets of dendritic cells resembling dermal DCs can be generated in vitro from monocytes, in the presence of different serum supplements.
Duperrier K, Eljaafari A, Dezutter-Dambuyant C, Bardin C, Jacquet C, Yoneda K, Schmitt D, Gebuhrer L, Rigal D., J. Immunol. Methods 238(1-2), 2000
PMID: 10758242
Internalization of monomeric lipopolysaccharide occurs after transfer out of cell surface CD14.
Vasselon T, Hailman E, Thieringer R, Detmers PA., J. Exp. Med. 190(4), 1999
PMID: 10449522
Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets.
Luft T, Jefford M, Luetjens P, Toy T, Hochrein H, Masterman KA, Maliszewski C, Shortman K, Cebon J, Maraskovsky E., Blood 100(4), 2002
PMID: 12149219
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P., J. Immunol. 160(4), 1998
PMID: 9469433
Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.
Romero P, Gervois N, Schneider J, Escobar P, Valmori D, Pannetier C, Steinle A, Wolfel T, Lienard D, Brichard V, van Pel A, Jotereau F, Cerottini JC., J. Immunol. 159(5), 1997
PMID: 9278327
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.
Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA., J. Exp. Med. 180(1), 1994
PMID: 7516411
Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity.
Pogue RR, Eron J, Frelinger JA, Matsui M., Proc. Natl. Acad. Sci. U.S.A. 92(18), 1995
PMID: 7545295
Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2.
Gotch F, Rothbard J, Howland K, Townsend A, McMichael A., Nature 326(6116), 1987
PMID: 2437457
Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.
Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, Snoke K, Serra HM, Kubo RT, Sette A., Immunity 1(9), 1994
PMID: 7895164
Bioprocess development for the cultivation of human T-lymphocytes in a clinical scale.
Bohnenkamp H, Hilbert U, Noll T., Cytotechnology 38(1-3), 2002
PMID: 19003095
Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix.
Manz R, Assenmacher M, Pfluger E, Miltenyi S, Radbruch A., Proc. Natl. Acad. Sci. U.S.A. 92(6), 1995
PMID: 7892200
Epitope characterization of MUC1 antibodies.
Blockzjil A, Nilsson K, Nilsson O., Tumour Biol. 19 Suppl 1(), 1998
PMID: 9422088
Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and in vitro
Walsh, Breast Cancer Res. Treat. 58(), 2000
T-cell responses of vaccinated cancer patients.
Coulie PG, van der Bruggen P., Curr. Opin. Immunol. 15(2), 2003
PMID: 12633661
Thymic selection generates a large T cell pool recognizing a self-peptide in humans.
Zippelius A, Pittet MJ, Batard P, Rufer N, de Smedt M, Guillaume P, Ellefsen K, Valmori D, Lienard D, Plum J, MacDonald HR, Speiser DE, Cerottini JC, Romero P., J. Exp. Med. 195(4), 2002
PMID: 11854361
Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis.
Reis e Sousa C, Germain RN., J. Exp. Med. 182(3), 1995
PMID: 7650490
Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.
Shen Z, Reznikoff G, Dranoff G, Rock KL., J. Immunol. 158(6), 1997
PMID: 9058806
Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization.
Kotera Y, Shimizu K, Mule JJ., Cancer Res. 61(22), 2001
PMID: 11719436
Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens.
Lambert LA, Gibson GR, Maloney M, Barth RJ Jr., J. Immunother. 24(3), 2001
PMID: 11394500
Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma using tumor lysate-pulsed dendritic cells.
Bachleitner-Hofmann T, Stift A, Friedl J, Pfragner R, Radelbauer K, Dubsky P, Schuller G, Benko T, Niederle B, Brostjan C, Jakesz R, Gnant M., J. Clin. Endocrinol. Metab. 87(3), 2002
PMID: 11889172
Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses.
Herr W, Ranieri E, Olson W, Zarour H, Gesualdo L, Storkus WJ., Blood 96(5), 2000
PMID: 10961887
Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
Schnurr M, Galambos P, Scholz C, Then F, Dauer M, Endres S, Eigler A., Cancer Res. 61(17), 2001
PMID: 11522639
Antigen loading of dendritic cells with whole tumor cell preparations.
Thumann P, Moc I, Humrich J, Berger TG, Schultz ES, Schuler G, Jenne L., J. Immunol. Methods 277(1-2), 2003
PMID: 12799035
Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells.
Kass R, Bellone S, Palmieri M, Cane S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD., Breast Cancer Res. Treat. 80(3), 2003
PMID: 14503800
Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy.
Wen YJ, Min R, Tricot G, Barlogie B, Yi Q., Blood 99(9), 2002
PMID: 11964294
Generation of tumor cell lysate-loaded dendritic cells preprogrammed for IL-12 production and augmented T cell response.
Vegh Z, Mazumder A., Cancer Immunol. Immunother. 52(2), 2003
PMID: 12594570
The instructive role of dendritic cells on T-cell responses.
Sallusto F, Lanzavecchia A., Arthritis Res. 4 Suppl 3(), 2002
PMID: 12110131
Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow.
Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Oberniedermayr M, Schirrmacher V, Umansky V., Nat. Med. 7(4), 2001
PMID: 11283672
Antigen bias in T cell cross-priming.
Wolkers MC, Brouwenstijn N, Bakker AH, Toebes M, Schumacher TN., Science 304(5675), 2004
PMID: 15166378
Epitope dominance, competition and T cell affinity maturation.
Kedl RM, Kappler JW, Marrack P., Curr. Opin. Immunol. 15(1), 2003
PMID: 12495743
Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 15919376
PubMed | Europe PMC

Suchen in

Google Scholar